Hypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Pedram Asadi-Sarabi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Hauptthemen laut MEDLINE: Regenerative Medicine, Pluripotent Stem Cells, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: Royan Institute.
Abstract (Originalsprache)
Hypoimmunogenic pluripotent stem cells (hPSCs) represent a transformative innovation in regenerative medicine, offering solutions to the longstanding challenge of immune rejection in cell-based therapies. Through advanced gene-editing techniques, particularly CRISPR/Cas9, hPSCs are engineered to downregulate or eliminate the expression of major histocompatibility complex (MHC) molecules while upregulating immunomodulatory proteins such as HLA-G, PD-L1, and CD47. These modifications enhance immune evasion and create the foundation for universal donor cells. Compared to conventional cell therapies that rely on lifelong immunosuppression, hPSC-based strategies offer safer, more sustainable, and patient-friendly solutions by minimizing the risks of infection, malignancy, and drug toxicity. Beyond immune compatibility, critical challenges persist, including the risk of tumorigenicity, off-target genetic alterations, and ethical considerations surrounding genome editing. Recent advances, such as the integration of suicide gene systems and sensitive monitoring assays, offer promising strategies to enhance the safety and functional stability of hPSC-derived therapies. This review comprehensively discusses the molecular engineering of hPSCs, their biomedical applications, safety strategies, ethical implications, and the evolving regulatory frameworks needed for clinical translation. By addressing both the scientific and societal dimensions, hPSCs have the potential to revolutionize personalized and off-the-shelf regenerative treatments, provided that rigorous safeguards are implemented.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Molecular Medicine Department, Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.
- Department of Cellular and Molecular Biology, Faculty of Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Biotechnology, Ege University Hospital, Izmir, Turkey.
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Förderung
- Royan Institute
Zitieren
APA
Asadi-Sarabi, P., Rismani, E., Shabanpouremam, M., Hendi, Z., Nikoubin, B., Rahimi, S., Taleb, M., Khosravi, A., Zarrabi, A., Hassan, M., & Vosough, M. (2025). Hypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115134
Vancouver
Asadi-Sarabi P, Rismani E, Shabanpouremam M, Hendi Z, Nikoubin B, Rahimi S, et al. Hypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115134
BibTeX
@article{AsadiSarabi2025,
author = {Asadi-Sarabi, Pedram and Rismani, Elham and Shabanpouremam, Mahshid and Hendi, Zahra and Nikoubin, Behnaz and Rahimi, Saina and Taleb, Mohammad and Khosravi, Arezoo and Zarrabi, Ali and Hassan, Moustapha and Vosough, Massoud},
title = {Hypoimmunogenic pluripotent stem cells: A game-changer in cell-based regenerative medicine},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115134}
}
EUVIMED